T3D Therapeutics Blog T3D Therapeutics Receives a Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program

RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2020 /PRNewswire/ — T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today that it has received a $740,000 grant from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program in support of clinical trial biomarker studies.  These […]